New Results
Treg cells drive MYCN-mediated immunosuppression and tumor aggressiveness in high-risk neuroblastoma
Xiaodan Qin, Andrew Lam, Xu Zhang, Satyaki Sengupta, J. Bryan Iorgulescu, Tao Zuo, Alexander E. Floru, Grace Meara, Liang Lin, Kenneth Lloyd, Lauren Kwok, Kaylee Smith, Raghavendar T. Nagaraju, Rob Meijers, Craig Ceol, View ORCID ProfileChing-Ti Liu, Sanda Alexandrescu, Catherine J. Wu, Derin B. Keskin, Rani E. George, Hui Feng
doi: https://doi.org/10.1101/2022.10.03.510561
Xiaodan Qin
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
Andrew Lam
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
Xu Zhang
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
2Guangdong Key Laboratory for Innovative Development and Utilization of Forest Plant Germplasm, College of Forestry and Landscape Architecture, South China Agricultural University, Guangzhou, Guangdong, CN
Satyaki Sengupta
3Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
J. Bryan Iorgulescu
4Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
5Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA
Tao Zuo
6Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
Alexander E. Floru
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
Grace Meara
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
Liang Lin
4Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Kenneth Lloyd
7Institute for Protein Innovation, Boston, MA, USA
Lauren Kwok
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
Kaylee Smith
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
Raghavendar T. Nagaraju
8Faculty of Biology, Medicine and Health, Division of Cancer Sciences, University of Manchester, Manchester, England, UK
9Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, England, UK
Rob Meijers
7Institute for Protein Innovation, Boston, MA, USA
Craig Ceol
10Department of Molecular Cell, and Cancer Biology, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA
Ching-Ti Liu
11Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
Sanda Alexandrescu
12Department of Pathology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
Catherine J. Wu
4Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
13Department of Medicine, Brigham and Women’s Hospital, Boston, Harvard Medical School, MA, USA
Derin B. Keskin
4Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
14Translational Immunogenomics Laboratory, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
15Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark
16Department of Computer Science, Metropolitan College, Boston University, Boston, MA, USA
Rani E. George
3Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Hui Feng
1Departments of Pharmacology and Medicine, Section of Hematology and Medical Oncology, The Cancer Center, Boston University School of Medicine, Boston, MA, USA
Article usage
Posted October 05, 2022.
Treg cells drive MYCN-mediated immunosuppression and tumor aggressiveness in high-risk neuroblastoma
Xiaodan Qin, Andrew Lam, Xu Zhang, Satyaki Sengupta, J. Bryan Iorgulescu, Tao Zuo, Alexander E. Floru, Grace Meara, Liang Lin, Kenneth Lloyd, Lauren Kwok, Kaylee Smith, Raghavendar T. Nagaraju, Rob Meijers, Craig Ceol, Ching-Ti Liu, Sanda Alexandrescu, Catherine J. Wu, Derin B. Keskin, Rani E. George, Hui Feng
bioRxiv 2022.10.03.510561; doi: https://doi.org/10.1101/2022.10.03.510561
Treg cells drive MYCN-mediated immunosuppression and tumor aggressiveness in high-risk neuroblastoma
Xiaodan Qin, Andrew Lam, Xu Zhang, Satyaki Sengupta, J. Bryan Iorgulescu, Tao Zuo, Alexander E. Floru, Grace Meara, Liang Lin, Kenneth Lloyd, Lauren Kwok, Kaylee Smith, Raghavendar T. Nagaraju, Rob Meijers, Craig Ceol, Ching-Ti Liu, Sanda Alexandrescu, Catherine J. Wu, Derin B. Keskin, Rani E. George, Hui Feng
bioRxiv 2022.10.03.510561; doi: https://doi.org/10.1101/2022.10.03.510561
Subject Area
Subject Areas
- Biochemistry (11562)
- Bioengineering (8622)
- Bioinformatics (28865)
- Biophysics (14793)
- Cancer Biology (11921)
- Cell Biology (17165)
- Clinical Trials (138)
- Developmental Biology (9302)
- Ecology (14019)
- Epidemiology (2067)
- Evolutionary Biology (18128)
- Genetics (12145)
- Genomics (16615)
- Immunology (11706)
- Microbiology (27690)
- Molecular Biology (11386)
- Neuroscience (60092)
- Paleontology (447)
- Pathology (1847)
- Pharmacology and Toxicology (3183)
- Physiology (4878)
- Plant Biology (10276)
- Synthetic Biology (2849)
- Systems Biology (7289)
- Zoology (1618)